{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?legislature.prefLabel=House+of+Commons&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&_metadata=all&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&legislature.prefLabel=House+of+Commons&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "items" : [{"_about" : "http://data.parliament.uk/resources/1690824", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1690824/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the processes that it uses, in the development of its recommendations on new medicines. The NICE will continue aiming to publish guidance on new medicines within 90 days of the receipt of a United Kingdom marketing authorisation, and is working closely with the Department, the Medicines and Healthcare products Regulatory Agency, industry, and system partners to ensure that it is able to make timely recommendations on new medicines licensed through the International Recognition Procedure.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-02-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-02-28T13:37:55.487Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-02-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that the National Institute for Health and Care Excellence's evaluation processes complement the Medicines and Healthcare products Regulatory Agency's International Recognition Procedure.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4792", "label" : {"_value" : "Biography information for Paul Bristow"}
      }
      , "tablingMemberConstituency" : {"_value" : "Peterborough"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Bristow"}
      ], "uin" : "15202"}
    , {"_about" : "http://data.parliament.uk/resources/1657697", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1657697/answer", "answerText" : {"_value" : "<p>The Department regularly meets with the National Institute for Health and Care Excellence (NICE) to discuss a range of issues. NICE\u2019s technology appraisal programme has been proven to be suitable for the assessment of innovative medicines and advanced therapy medicinal products (ATMPs) where companies are able to price their products in a way that represents value to the taxpayer.<\/p><p>NICE has recommended several ATMPs through its technology appraisal programme that are now available to patients in the National Health Service. NICE concluded a review of its methods and processes for health technology evaluation in January 2022 and has introduced changes that ensure that its appraisal processes are suitable for emerging new medicines, including a broader severity modifier and changes to better respond to uncertainty.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-09-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-09-11T13:30:18.367Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-09-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he has held discussions with the National Institute for Health and Care Excellence on the adequacy of the single technology appraisal pathway for the assessment of (a) innovative technologies and (b) advanced therapy medicinal products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "197395"}
    , {"_about" : "http://data.parliament.uk/resources/1654470", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1654470/answer", "answerText" : {"_value" : "<p>The Department has not issued any such guidance. The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes that it uses in the development of its guidance, including the criteria used to determine whether topics should be routed to the technology appraisal or highly specialised technologies programmes. NICE made changes to its health technology evaluation manual in January 2022 following a comprehensive review of its methods and processes, including public consultation. As part of these changes, the eligibility criteria for the highly specialised technologies programme were clarified to make them clearer and more predictable.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-09-04", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-09-04T10:12:05.27Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-07-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has provided guidance to NICE on the evidence used to inform the criteria updates to its Highly Specialised Technology processes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leeds North West"}
      , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
      ], "uin" : "195282"}
    , {"_about" : "http://data.parliament.uk/resources/1653811", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1653811/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the decision-making processes that it operates.<\/p><p>NICE\u2019s Topic Selection Oversight Panel (TSOP) is responsible for the selection of topics for guidance development in the Centre for Health Technology Evaluation. The group considers the available evidence as well as clinical and patient insights to apply the medicines and highly specialised technologies criteria and\u202fdecide whether to route medicines to the technology appraisal or highly specialised technologies programmes, or to deselect the topic. The TSOP\u2019s membership includes lay members to provide the perspective of patients, people who use services and carers in the selection and routing of topics. It also includes members with responsibility for providing clinical insights and expertise.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-09-04", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-09-04T09:38:40.52Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-07-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that NICE\u2019s Topic Selection Oversight Panel considers (a) clinical and (b) patient expert insights in its decision-making processes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leeds North West"}
      , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
      ], "uin" : "194779"}
    , {"_about" : "http://data.parliament.uk/resources/1416468", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1416468/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) has rescheduled one appraisal of an oncology technology in the last six months for operational reasons. NICE\u2019s appraisal of pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer has been delayed by approximately three months due to the volume of topics in its work programme. NICE\u2019s final guidance is expected to be published in November 2022.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2022-01-31", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-31T17:57:59.237Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 January 2022 to Question 96910 on National Institute for Health and Care Excellence, how many oncology technical appraisals have been rescheduled in the last six months directly as a result of NICE operational challenges; and what the average time taken has been to reschedule those appraisals.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "111625"}
    , {"_about" : "http://data.parliament.uk/resources/1399150", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1399150/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is committed to publishing draft recommendations on new medicines around the time of licensing, with final guidance within three months of licensing wherever possible. The Department holds regular accountability meetings with NICE on a range of topics, including capacity issues. NICE delivers timely guidance on new medicines in the vast majority of cases and expects to continue to do so.<\/p><p>Project Orbis has been established to allow participating partners, including the United Kingdom, to review and approve applications for promising cancer treatments efficiently. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are ensuring an integrated, timely approach to access new products, including those licensed through Project Orbis. NHS England and NHS Improvement and NICE have agreed principles to allow potential interim access ahead of NICE\u2019s guidance where timely guidance is not anticipated, which has supported early patient access for a number of medicines licensed through Project Orbis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2022-01-11", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "96909"}
        , {"_value" : "96910"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-11T09:29:32.533Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on their (a) current and (b) future capacity to deliver final draft guidance on medicines within three months of regulatory approval by the MHRA.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "96908"}
    , {"_about" : "http://data.parliament.uk/resources/1399156", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1399156/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is committed to publishing draft recommendations on new medicines around the time of licensing, with final guidance within three months of licensing wherever possible. The Department holds regular accountability meetings with NICE on a range of topics, including capacity issues. NICE delivers timely guidance on new medicines in the vast majority of cases and expects to continue to do so.<\/p><p>Project Orbis has been established to allow participating partners, including the United Kingdom, to review and approve applications for promising cancer treatments efficiently. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are ensuring an integrated, timely approach to access new products, including those licensed through Project Orbis. NHS England and NHS Improvement and NICE have agreed principles to allow potential interim access ahead of NICE\u2019s guidance where timely guidance is not anticipated, which has supported early patient access for a number of medicines licensed through Project Orbis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2022-01-11", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "96908"}
        , {"_value" : "96909"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-11T09:29:32.66Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of operational challenges faced by NICE on its ability to deliver timely patient access to new medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "96910"}
    , {"_about" : "http://data.parliament.uk/resources/1385862", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1385862/answer", "answerText" : {"_value" : "<p>Departmental officials regularly discuss a range of issues with the National Institute for Health and Care Excellence (NICE), including the ongoing methods and process review.<\/p><p>NICE recommends the vast majority of medicines it appraises. It has consulted on proposed changes to its methods and processes which will ensure it retains global leadership in the evaluation of new medicines and technologies and provides more equitable access for patients with severe diseases. NICE has undertaken analysis of the impact of its proposed methods in developing the proposals.<\/p><p>NICE is proposing a number of changes to ensure its methods and process are fairer, more consistent and accelerate the introduction of emerging new types of technology. This will support the Life Sciences Vision\u2019s commitment to make the United Kingdom the best place in the world to develop, trial, launch and adopt innovative new medicines, improving patient access to medicines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2021-12-15", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "88743"}
        , {"_value" : "88745"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-12-15T17:02:13.447Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the NICE Methods Review, if he will hold discussions with NICE in the event that its new methods for appraising medicines impact on the number of patients receiving access to promising treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "88744"}
    , {"_about" : "http://data.parliament.uk/resources/1385863", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1385863/answer", "answerText" : {"_value" : "<p>Departmental officials regularly discuss a range of issues with the National Institute for Health and Care Excellence (NICE), including the ongoing methods and process review.<\/p><p>NICE recommends the vast majority of medicines it appraises. It has consulted on proposed changes to its methods and processes which will ensure it retains global leadership in the evaluation of new medicines and technologies and provides more equitable access for patients with severe diseases. NICE has undertaken analysis of the impact of its proposed methods in developing the proposals.<\/p><p>NICE is proposing a number of changes to ensure its methods and process are fairer, more consistent and accelerate the introduction of emerging new types of technology. This will support the Life Sciences Vision\u2019s commitment to make the United Kingdom the best place in the world to develop, trial, launch and adopt innovative new medicines, improving patient access to medicines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2021-12-15", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "88743"}
        , {"_value" : "88744"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-12-15T17:02:13.493Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will hold discussions with NICE on ensuring that their Methods Review achieves the Government's commitment for life sciences as set out in the Life Sciences Vision, published in July 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "88745"}
    , {"_about" : "http://data.parliament.uk/resources/1271496", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1271496/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is an independent body and is therefore responsible for its own methods and processes for evaluations and approving new medicines and treatments. Consultee organisations for NICE\u2019s technology appraisals include national groups representing patients and carers.<\/p><p>NICE has had patient involvement throughout its methods and process review, including a specific workstream led by patient representatives and senior NICE staff. Patient groups are also represented on its Methods Review Working Group.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2021-01-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1271496/answer/previousversion/72723", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
          }
          , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
          , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        }
        , "questionFirstAnswered" : [{"_value" : "2021-01-27T15:29:38.173Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-12-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the level of patient involvement in the NICE process for evaluating and approving new medicines and treatment; and whether there are plans under the ongoing Methods Review to adjust that level of involvement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4641", "label" : {"_value" : "Biography information for Alex Norris"}
      }
      , "tablingMemberConstituency" : {"_value" : "Nottingham North"}
      , "tablingMemberPrinted" : [{"_value" : "Alex Norris"}
      ], "uin" : "130207"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&legislature.prefLabel=House+of+Commons&min-answer.questionFirstAnswered.=2019-05-15T12%3A39%3A20.147Z&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "page" : 0, "startIndex" : 1, "totalResults" : 29, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}